

Carsten Bokemeyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/512764/publications.pdf>

Version: 2024-02-01

219
papers

6,457
citations

136950

32
h-index

85541

71
g-index

222
all docs

222
docs citations

222
times ranked

12985
citing authors

#	ARTICLE	IF	CITATIONS
1	How does spirituality manifest in family caregivers of terminally ill cancer patients? A qualitative secondary analysis. <i>Palliative and Supportive Care</i> , 2022, 20, 45-54.	1.0	4
2	COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2022, 63, 664-671.	1.3	4
3	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. <i>Leukemia</i> , 2022, 36, 885-888.	7.2	38
4	Acceptance and Benefits of Two Different Strategies to Timely Integrate Specialist Palliative Care into Routine Cancer Care: A Randomized Pilot Study. <i>Oncology Research and Treatment</i> , 2022, 45, 118-129.	1.2	2
5	Non-Random Pattern of Integration for Epstein-Barr Virus with Preference for Gene-Poor Genomic Chromosomal Regions into the Genome of Burkitt Lymphoma Cell Lines. <i>Viruses</i> , 2022, 14, 86.	3.3	6
6	Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia—A Single Center Analysis. <i>Antibiotics</i> , 2022, 11, 128.	3.7	2
7	Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSC). <i>World Journal of Urology</i> , 2022, 40, 355-361.	2.2	2
8	Surgical Site Cytology to Diagnose Spinal Lesions. <i>Diagnostics</i> , 2022, 12, 310.	2.6	0
9	Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2022, 40, 80-80.	1.6	0
10	Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer—≥ 70 years. <i>European Journal of Cancer</i> , 2022, 163, 1-15.	2.8	6
11	First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment. <i>World Journal of Urology</i> , 2022, , 1.	2.2	1
12	Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	1
13	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3
14	Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1084.	3.7	3
15	Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2569.	4.1	11
16	What are the personal last wishes of people with a life-limiting illness? Findings from a longitudinal observational study in specialist palliative care. <i>BMC Palliative Care</i> , 2022, 21, 38.	1.8	2
17	Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by $\hat{I}^3\hat{I}$ T Cells in Ovarian Cancer. <i>Cells</i> , 2022, 11, 964.	4.1	19
18	Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. <i>Cancers</i> , 2022, 14, 1793.	3.7	3

#	ARTICLE	IF	CITATIONS
19	Study of Structure-Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents. <i>Marine Drugs</i> , 2022, 20, 185.	4.6	9
20	Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation. <i>British Journal of Haematology</i> , 2022, , .	2.5	1
21	RANKL regulates testicular cancer growth and Denosumab treatment has suppressive effects on GCNIS and advanced seminoma. <i>British Journal of Cancer</i> , 2022, 127, 408-421.	6.4	2
22	Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients- COVIDOUT study. <i>Cancer Cell</i> , 2022, 40, 581-583.	16.8	7
23	How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence. <i>World Journal of Urology</i> , 2022, 40, 2863-2878.	2.2	7
24	Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment. <i>Cancers</i> , 2022, 14, 2773.	3.7	1
25	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. <i>Cancer Research</i> , 2022, 82, 3374-3374.	0.9	1
26	Overall survival (OS) of patients with TRK fusion-positive cancer receiving larotrectinib versus standard of care (SoC): A matching-adjusted indirect comparison (MAIC) using real-world data (RWD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 6579-6579.	1.6	0
27	Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3572-3572.	1.6	1
28	First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3578-3578.	1.6	0
29	Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine. <i>Leukemia and Lymphoma</i> , 2022, 63, 2645-2651.	1.3	2
30	The prognostic impact of the smoking status of cancer patients receiving systemic treatment, radiation therapy, and surgery: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 172, 130-137.	2.8	5
31	Supportive care needs and service use during palliative care in family caregivers of patients with advanced cancer: a prospective longitudinal study. <i>Supportive Care in Cancer</i> , 2021, 29, 1303-1315.	2.2	28
32	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	6.4	5
33	Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation. <i>Thrombosis Research</i> , 2021, 198, 55-61.	1.7	7
34	Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation. <i>Oncology Research and Treatment</i> , 2021, 44, 375-381.	1.2	5
35	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	3
36	In vitro and in vivo investigations of novel 1,4-naphthoquinone sulphomethylene carbohydrate conjugates in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 104-104.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 123-123.	1.6	1
38	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World Journal of Urology, 2021, 39, 3407-3414.	2.2	4
39	Effects of a structured counselling-based intervention to improve physical activity behaviour of adolescents and young adult cancer survivors – the randomized phase II Motivate AYA – MAYA trial. Clinical Rehabilitation, 2021, 35, 1164-1174.	2.2	9
40	Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nature Reviews Urology, 2021, 18, 227-245.	3.8	49
41	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. Journal of the National Cancer Institute, 2021, 113, 1386-1395.	6.3	17
42	Existential distress in patients with advanced cancer and their caregivers: study protocol of a longitudinal cohort study. BMJ Open, 2021, 11, e046351.	1.9	10
43	Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database.. Journal of Clinical Oncology, 2021, 39, 3610-3610.	1.6	0
44	Development and preliminary psychometric investigation of the German Satisfaction with Comprehensive Cancer Care (SCCC) Questionnaire. Health and Quality of Life Outcomes, 2021, 19, 147.	2.4	6
45	Thoughts of death and suicidality among patients with cancer: Examining subtypes and their association with mental disorders. Psycho-Oncology, 2021, 30, 2023-2031.	2.3	11
46	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	1.6	83
47	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	1.6	108
48	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 1705-1713.	6.3	12
49	Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. Cancers, 2021, 13, 3800.	3.7	27
50	Immune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19). Blood, 2021, 138, 996-999.	1.4	15
51	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. , 2021, 9, e002844.		29
52	Gender-specific problems and needs of family caregivers during specialist inpatient palliative care: a qualitative study on experiences of family caregivers and healthcare professionals. Annals of Palliative Medicine, 2021, 10, 8571-8583.	1.2	3
53	Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case. Leukemia and Lymphoma, 2021, , 1-5.	1.3	1
54	Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells. Pharmaceuticals, 2021, 14, 949.	3.8	6

#	ARTICLE	IF	CITATIONS
55	Perceived Positive and Negative Life Changes in Testicular Cancer Survivors. <i>Medicina (Lithuania)</i> , 2021, 57, 993.	2.0	3
56	The developmental origin of cancers defines basic principles of cisplatin resistance. <i>Cancer Letters</i> , 2021, 519, 199-210.	7.2	17
57	Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10670.	4.1	6
58	Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a <i>bcr-abl</i> ROS1 Mutation: Case Report. <i>Oncology Research and Treatment</i> , 2021, 44, 495-502.	1.2	5
59	Comparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100 [®] in patients undergoing neuroendovascular procedures. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 383-392.	2.3	4
60	Bone Marrow-Resident $\gamma\delta$ T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma. <i>Frontiers in Medicine</i> , 2021, 8, 763773.	2.6	21
61	Evaluation of an electronic psycho-oncological adaptive screening program (EPAS) with immediate patient feedback: findings from a German cluster intervention study. <i>Journal of Cancer Survivorship</i> , 2021, , 1.	2.9	1
62	Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12919.	4.1	27
63	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. <i>Oncology Research and Treatment</i> , 2021, 44, 690-699.	1.2	11
64	Evaluation of a program for routine implementation of shared decision-making in cancer care: results of a stepped wedge cluster randomized trial. <i>Implementation Science</i> , 2021, 16, 106.	6.9	13
65	Prevalence and Predictors of Distress, Anxiety, Depression, and Quality of Life in Bereaved Family Caregivers of Patients With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 201-213.	1.4	42
66	Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 2.	6.2	27
67	Individual specialist physical activity assessment and intervention in advanced cancer patients on a palliative care ward; the 3STEPS-study. <i>Annals of Palliative Medicine</i> , 2020, 9, 4315-4322.	1.2	1
68	The Impact of Smoking Cessation and Continuation on Recurrence and Survival in Patients with Head and Neck Cancer: A Systematic Review of the Literature. <i>Oncology Research and Treatment</i> , 2020, 43, 549-558.	1.2	18
69	Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 268-277.	3.9	1,954
70	Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells. <i>Marine Drugs</i> , 2020, 18, 609.	4.6	14
71	Tipping point: When patients stop eating and drinking in the last phase of their life. <i>Clinical Nutrition ESPEN</i> , 2020, 38, 280-282.	1.2	1
72	Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5084.	4.1	15

#	ARTICLE	IF	CITATIONS
73	Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells. <i>Histochemistry and Cell Biology</i> , 2020, 153, 367-377.	1.7	10
74	Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3267-3279.	3.8	4
75	Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties. <i>Scientific Reports</i> , 2020, 10, 13178.	3.3	10
76	Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. <i>Cancers</i> , 2020, 12, 2467.	3.7	11
77	Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. <i>Future Oncology</i> , 2020, 16, 3035-3043.	2.4	18
78	Assessing palliative care need in left ventricular assist device patients and heart transplant recipients. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 874-880.	1.1	2
79	Ethical challenges in family caregivers of patients with advanced cancer – a qualitative study. <i>BMC Palliative Care</i> , 2020, 19, 70.	1.8	19
80	Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer. <i>Marine Drugs</i> , 2020, 18, 251.	4.6	23
81	Evaluation of a communication skills training to facilitate addressing palliative care related topics in advanced cancer patients: study protocol of a multicenter randomized controlled trial (PALLI-KOM). <i>BMC Palliative Care</i> , 2020, 19, 67.	1.8	3
82	Systematic symptom and problem assessment at admission to the palliative care ward – perspectives and prognostic impacts. <i>BMC Palliative Care</i> , 2020, 19, 75.	1.8	11
83	Human chorionic gonadotropin- α positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	2.8	8
84	Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO) Tj ETQq0 0 0.6BT /Overlock 10 T	2.8	23
85	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group – Molecular Diagnostics and Therapy™. <i>European Journal of Cancer</i> , 2020, 135, 1-7.	2.8	23
86	Urupocidin C: a new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting. <i>Scientific Reports</i> , 2020, 10, 9764.	3.3	18
87	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e169-e173.	2.5	14
88	Polyphenolic Compounds from <i>Lespedeza Bicolor</i> Root Bark Inhibit Progression of Human Prostate Cancer Cells via Induction of Apoptosis and Cell Cycle Arrest. <i>Biomolecules</i> , 2020, 10, 451.	4.0	23
89	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. <i>Scientific Reports</i> , 2020, 10, 3250.	3.3	18
90	Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling. <i>Frontiers in Oncology</i> , 2020, 9, 1559.	2.8	0

#	ARTICLE	IF	CITATIONS
91	Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 3.	2.4	11
92	Impact, challenges and limits of inpatient palliative care consultations – perspectives of requesting and conducting physicians. <i>BMC Health Services Research</i> , 2020, 20, 86.	2.2	6
93	Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMC-CONCEPT trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8508-8508.	1.6	21
94	Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 188-188.	1.6	2
95	How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 89-89.	1.6	1
96	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).. <i>Journal of Clinical Oncology</i> , 2020, 38, 96-96.	1.6	41
97	Prognostic impact of LDH and HCG levels in marker-positive seminomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 392-392.	1.6	4
98	Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. <i>Current Cancer Drug Targets</i> , 2020, 20, 811-817.	1.6	8
99	Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts) with KRAS, NRAS, and BRAF mutation (MT) status: Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4090-4090.	1.6	0
100	Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study. <i>JMIR Research Protocols</i> , 2020, 9, e17854.	1.0	2
101	Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma. <i>Biomarkers in Medicine</i> , 2020, 14, 1651-1662.	1.4	0
102	Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 402-402.	1.6	0
103	Increased Frequency of TOX+ CD39+ TIGIT+ CD73- CD8+ T Cells in Patients with Newly Diagnosed AML. <i>Blood</i> , 2020, 136, 36-36.	1.4	0
104	A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 334-340.	1.3	7
105	The P2-receptor-mediated Ca ²⁺ signalosome of the human pulmonary endothelium - implications for pulmonary arterial hypertension. <i>Purinergic Signalling</i> , 2019, 15, 299-311.	2.2	21
106	Exploring the gender dimension of problems and needs of patients receiving specialist palliative care in a German palliative care unit - the perspectives of patients and healthcare professionals. <i>BMC Palliative Care</i> , 2019, 18, 59.	1.8	17
107	New Trisulfated Steroids from the Vietnamese Marine Sponge <i>Halichondria vansoesti</i> and Their PSA Expression and Glucose Uptake Inhibitory Activities. <i>Marine Drugs</i> , 2019, 17, 445.	4.6	9
108	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. <i>Oncolimmunology</i> , 2019, 8, e1674605.	4.6	59

#	ARTICLE	IF	CITATIONS
109	Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones. <i>Cancers</i> , 2019, 11, 1690.	3.7	34
110	The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 809.e19-809.e25.	1.6	10
111	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 857-868.	5.1	12
112	<p>Impact of taste and smell training on taste disorders during chemotherapy â€“ TASTE trial</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4493-4504.	1.9	26
113	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2019, 11, 835.	3.7	109
114	Fatal Myelotoxicity Following Palliative Chemotherapy With Cisplatin and Gemcitabine in a Patient With Stage IV Cholangiocarcinoma Linked to Post Mortem Diagnosis of Fanconi Anemia. <i>Frontiers in Oncology</i> , 2019, 9, 420.	2.8	14
115	Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 823-833.	4.1	27
116	Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. <i>Tumori</i> , 2019, 105, NP8-NP11.	1.1	1
117	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1663.	3.7	10
118	Psychological burden in family caregivers of patients with advanced cancer at initiation of specialist inpatient palliative care. <i>BMC Palliative Care</i> , 2019, 18, 102.	1.8	59
119	Challenges Faced by Prehospital Emergency Physicians Providing Emergency Care to Patients with Advanced Incurable Diseases. <i>Emergency Medicine International</i> , 2019, 2019, 1-11.	0.8	14
120	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 717-723.	2.5	25
121	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4120-4120.	1.6	2
122	Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS6095-TPS6095.	1.6	2
123	Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3539-3539.	1.6	0
124	Effects of a structured intervention program to improve physical activity (PA) of adolescents and young adult cancer survivors (AYAs): Final results of the randomized Motivate AYAâ€“MAYA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11518-11518.	1.6	1
125	Blockade of Myeloid-Derived Suppressor Cell Expansion with All- <i>Trans</i> Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. <i>Cancer Research</i> , 2018, 78, 3220-3232.	0.9	84
126	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. <i>Oncolimmunology</i> , 2018, 7, e1417720.	4.6	10

#	ARTICLE	IF	CITATIONS
127	Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors. <i>European Journal of Cancer</i> , 2018, 94, 16-25.	2.8	10
128	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. <i>Haematologica</i> , 2018, 103, 939-948.	3.5	23
129	Therapeutic approaches for refractory germ cell cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 389-397.	2.4	33
130	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. <i>Cancer Letters</i> , 2018, 423, 60-70.	7.2	31
131	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITC (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018, 103, 205-213.	2.8	13
132	Palliative treatment of germ cell cancer. <i>Cancer Treatment Reviews</i> , 2018, 71, 102-107.	7.7	19
133	Identification of a High-Level MET Amplification in CTCs and cTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e243-e246.	1.1	18
134	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. <i>Oncogene</i> , 2018, 37, 5269-5280.	5.9	65
135	Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial. <i>Implementation Science</i> , 2018, 13, 51.	6.9	25
136	Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis. <i>Blood</i> , 2018, 132, 1922-1922.	1.4	3
137	Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (mCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3561-3561.	1.6	20
138	Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 612-612.	1.6	2
139	Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 748-748.	1.6	9
140	Synthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16962-16973.	1.8	15
141	Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients. <i>Oncotarget</i> , 2018, 9, 34794-34809.	1.8	3
142	Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-617.	1.6	0
143	The effects of music therapy in patients with high-dose chemotherapy and stem cell support: a randomized pilot study. <i>Psycho-Oncology</i> , 2017, 26, 377-384.	2.3	26
144	The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells. <i>BMC Cancer</i> , 2017, 17, 93.	2.6	42

#	ARTICLE	IF	CITATIONS
145	Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin. <i>Proteomics</i> , 2017, 17, 1700048.	2.2	8
146	Fronodoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. <i>Leukemia and Lymphoma</i> , 2017, 58, 2905-2915.	1.3	26
147	Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. <i>Haematologica</i> , 2017, 102, e368-e370.	3.5	48
148	MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2480-2484.	1.3	2
149	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. <i>International Journal of Cancer</i> , 2017, 140, 2535-2544.	5.1	42
150	Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism. <i>Cancer Research</i> , 2017, 77, 1188-1199.	0.9	71
151	Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1319-1325.	2.5	26
152	Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2017, 17, 72.	2.0	30
153	Quality of life, psychological burden, needs, and satisfaction during specialized inpatient palliative care in family caregivers of advanced cancer patients. <i>BMC Palliative Care</i> , 2017, 16, 31.	1.8	122
154	Platinum-refractory germ cell tumors: an update on current treatment options and developments. <i>World Journal of Urology</i> , 2017, 35, 1167-1175.	2.2	25
155	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2289-2300.	7.0	38
156	Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. <i>Journal of Clinical Oncology</i> , 2017, 35, 675-675.	1.6	4
157	Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study. <i>Journal of Clinical Oncology</i> , 2017, 35, 769-769.	1.6	3
158	Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 29187-29201.	1.8	28
159	Cyclin D1 gene amplification is highly homogeneous in breast cancer. <i>Breast Cancer</i> , 2016, 23, 111-119.	2.9	33
160	Pretrichodermamides D-F from a Marine Algicolous Fungus <i>Penicillium</i> sp. KMM 4672. <i>Marine Drugs</i> , 2016, 14, 122.	4.6	41
161	Guanidine Alkaloids from the Marine Sponge <i>Monanchora pulchra</i> Show Cytotoxic Properties and Prevent EGF-Induced Neoplastic Transformation in Vitro. <i>Marine Drugs</i> , 2016, 14, 133.	4.6	48
162	The marine triterpene glycoside frondoside A exhibits activity <i>in vitro</i> and <i>in vivo</i> in prostate cancer. <i>International Journal of Cancer</i> , 2016, 138, 2450-2465.	5.1	60

#	ARTICLE	IF	CITATIONS
163	A transplant "immunome"-screening platform defines a targetable epitope fingerprint of multiple myeloma. <i>Blood</i> , 2016, 127, 3202-3214.	1.4	7
164	Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1979-1994.	2.5	10
165	Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2016, 16, 145.	2.0	18
166	Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2016, 97, 239-244.	2.2	9
167	Hodgkin's lymphoma as a rare variant of Richter's transformation in chronic lymphocytic leukemia: A case report and review of the literature. <i>Molecular and Clinical Oncology</i> , 2016, 4, 390-392.	1.0	7
168	Investigational targeted therapies for the treatment of testicular germ cell tumors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1033-1043.	4.1	25
169	Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 144-152.	3.2	7
170	Symptom burden in long-term germ cell tumor survivors. <i>Supportive Care in Cancer</i> , 2016, 24, 2243-2250.	2.2	18
171	Anti-migratory activity of marine alkaloid monanchocidin A " proteomics-based discovery and confirmation. <i>Proteomics</i> , 2016, 16, 1590-1603.	2.2	17
172	Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 523-527.	0.9	8
173	The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 483-492.	2.8	14
174	Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care Registry data from an outcomes research project of the German Testicular Cancer Study Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 168.e21-168.e28.	1.6	25
175	Prospective Study on Music Therapy in Terminally Ill Cancer Patients during Specialized Inpatient Palliative Care. <i>Journal of Palliative Medicine</i> , 2016, 19, 394-399.	1.1	16
176	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. <i>Pathology and Oncology Research</i> , 2016, 22, 95-102.	1.9	19
177	High Ki67 expression is an independent good prognostic marker in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2016, 69, 209-214.	2.0	114
178	Marine compound rhizochalinin shows high <i>in vitro</i> and <i>in vivo</i> efficacy in castration resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 69703-69717.	1.8	16
179	Improved Nutrition in Adolescents and Young Adults after childhood cancer: INAYA " A pilot study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 173-173.	1.6	0
180	Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): A Global Germ Cell Cancer Group (G3) Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16058-e16058.	1.6	0

#	ARTICLE	IF	CITATIONS
181	A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 833-42.	5.3	16
182	The polyphosphate factor XII pathway drives coagulation in prostate cancer-associated thrombosis. <i>Blood</i> , 2015, 126, 1379-1389.	1.4	117
183	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. <i>Diagnostic Pathology</i> , 2015, 10, 125.	2.0	25
184	Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. <i>Oncotarget</i> , 2015, 6, 6341-6358.	1.8	28
185	Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. <i>Oncotarget</i> , 2015, 6, 12035-12047.	1.8	60
186	The Preference to Discuss Expected Survival Is Associated with Loss of Meaning and Purpose in Terminally Ill Cancer Patients. <i>Journal of Palliative Medicine</i> , 2015, 18, 970-976.	1.1	19
187	Peritumoral eosinophils predict recurrence in colorectal cancer. <i>Modern Pathology</i> , 2015, 28, 403-413.	5.5	56
188	Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients. <i>Journal of Cancer Survivorship</i> , 2015, 9, 567-575.	2.9	74
189	Expression of Hedgehog Pathway Mediator <i>GLI1</i> Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. <i>Clinical Cancer Research</i> , 2015, 21, 2388-2398.	7.0	88
190	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. <i>BMC Gastroenterology</i> , 2015, 15, 7.	2.0	101
191	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. <i>Blood</i> , 2015, 126, 3789-3789.	1.4	3
192	Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization. <i>Oncotarget</i> , 2015, 6, 17328-17341.	1.8	61
193	Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3555-3555.	1.6	0
194	Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15570-e15570.	1.6	0
195	Epidermal growth factor receptor mutations may confer resistance or cross-resistance to cetuximab and panitumumab and can be detected in circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3549-3549.	1.6	0
196	BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1569-1569.	1.4	0
197	Aptamines from the Marine Sponge <i>Aaptos</i> sp. Display Anticancer Activities in Human Cancer Cell Lines and Modulate AP-1, NF- κ B, and p53-Dependent Transcriptional Activity in Mouse JB6 Cl41 Cells. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	39
198	Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: Secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 497-515.	2.8	16

#	ARTICLE	IF	CITATIONS
199	The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study. <i>Clinical Cancer Research</i> , 2014, 20, 3348-3357.	7.0	17
200	Quinone-carbohydrate nonglucoside conjugates as a new type of cytotoxic agents: Synthesis and determination of in vitro activity. <i>European Journal of Medicinal Chemistry</i> , 2014, 77, 139-144.	5.5	31
201	Activity of aaptamine and two derivatives, demethyloxyaaptamine and iso-aaptamine, in cisplatin-resistant germ cell cancer. <i>Journal of Proteomics</i> , 2014, 96, 223-239.	2.4	43
202	Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. <i>Journal of Clinical Oncology</i> , 2014, 32, 3505-3505.	1.6	41
203	Changes in items of a comprehensive geriatric assessment (CGA) during follow-up: Results from the IN-GHO registry. <i>Journal of Clinical Oncology</i> , 2014, 32, 9547-9547.	1.6	4
204	A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer (RADIT). <i>Journal of Clinical Oncology</i> , 2014, 32, e15535-e15535.	1.6	1
205	Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA444-LBA444.	1.6	26
206	N-Terminal Pro-Brain Natriuretic Peptide Is a Useful Prognostic Marker in Patients with Pre-Capillary Pulmonary Hypertension and Renal Insufficiency. <i>PLoS ONE</i> , 2014, 9, e94263.	2.5	14
207	Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. <i>Oncotarget</i> , 2014, 5, 6647-6653.	1.8	27
208	Molecular profiling of testicular cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 4515-4515.	1.6	0
209	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	1.4	1
210	The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2533-2542.	3.3	21
211	Prognostic factors for the efficacy of catumaxomab in patients (pts) with malignant ascites (MA): Meta-analysis from two phase III studies. <i>Journal of Clinical Oncology</i> , 2013, 31, 3078-3078.	1.6	0
212	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. <i>European Journal of Cancer</i> , 2012, 48, 1466-1475.	2.8	506
213	Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: Potentials as therapeutic target. <i>Oral Oncology</i> , 2012, 48, 991-996.	1.5	31
214	The clonality of immunoglobulin repertoire in prostate cancer-infiltrating B cells. <i>Journal of Clinical Oncology</i> , 2012, 30, e15168-e15168.	1.6	0
215	Expression of Cancer-Testis Antigens MAGE-C1/CT7 and MAGE-A3 Is Central to the Survival of Myeloma Cells and Their Resistance to Chemotherapy. <i>Blood</i> , 2008, 112, 3668-3668.	1.4	1
216	No Adverse Impact of 13q14 and P53 Deletion, t(4;14)(p16;q32) or Overrepresentation of CMYC(8q24) as Detected by Fluorescence In Situ Hybridization on Outcome in Patients with Multiple Myeloma Following Dose-Reduced Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2006, 108, 5038-5038.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors.. Blood, 2006, 108, 3947-3947.	1.4	0
218	Cilengitide Inhibits Proliferation and Differentiation of Human Endothelial Progenitor Cells In Vitro.. Blood, 2006, 108, 3929-3929.	1.4	0
219	Multiple Myeloma Patients Treated with Allogeneic Stem Cell Transplantation Show an Increased Frequency of Bone Marrow-Residing CD4+Foxp3+ T Regulatory Cells.. Blood, 2006, 108, 5206-5206.	1.4	0